The solithromycin journey—It is all in the chemistry

Bioorganic and Medicinal Chemistry

Volumn 24, Issue 24, 2016, Pages 6420-6428

  Fernandes, Prabhavathi ^a   Martens, Evan ^a   Bertrand, Daniel ^b   Pereira, David ^a  

^a Cempra Pharmaceuticals Inc   (United States)

^b HiQScreen Sarl   (Switzerland)

Author keywords

Antibiotic resistance; Fluroketolide; Macrolide; Pneumonia; Solithromycin

Indexed keywords

AZITHROMYCIN; LEVOFLOXACIN; SOLITHROMYCIN; TELITHROMYCIN; ANTIINFECTIVE AGENT; MACROLIDE; TRIAZOLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; CHLAMYDIASIS; COMMUNITY ACQUIRED BACTERIAL PNEUMONIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GONORRHEA; HUMAN; LIVER TOXICITY; MYASTHENIA GRAVIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG DOSE; X RAY CRYSTALLOGRAPHY; BACTERIUM; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; RESPIRATORY TRACT INFECTIONS; TRIAZOLES;

EID: 84997327902     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2016.08.035     Document Type: Article

References (68)

1. 1 Farrell, D.J., Flamm, R.K., Sader, H.S., Jones, R.N., Antimicrob. Agents Chemother., 60, 2016, 3662.
2. 2 Kim, S.H., Song, J.H., Chung, D.R., Thamlikitkul, V., Yang, Y., Wang, H., Lu, M., So, T.M., Hsueh, P.R., Yasin, R.M., Carlos, C.C., Pham, H.V., Lalitha, M.K., Shimono, N., Perera, J., Shibl, A.M., Baek, J.Y., Kang, C.I., Ko, K.S., Peck, K.R., Group, A.S., Antimicrob. Agents Chemother., 56, 2012, 1418.
3. 3 Spellberg, B., Bartlett, J.G., Gilbert, D.N., N. Engl. J. Med., 368, 2013, 299.
4. 4 Tamma, P.D., Cosgrove, S.E., JAMA, 315, 2016, 1839.
5. 5 Spellberg, B., Srinivasan, A., Chambers, H.F., JAMA, 315, 2016, 1229.
6. 6 Jain, S., Self, W.H., Wunderink, R.G., Fakhran, S., Balk, R., Bramley, A.M., Reed, C., Grijalva, C.G., Anderson, E.J., Courtney, D.M., Chappell, J.D., Qi, C., Hart, E.M., Carroll, F., Trabue, C., Donnelly, H.K., Williams, D.J., Zhu, Y., Arnold, S.R., Ampofo, K., Waterer, G.W., Levine, M., Lindstrom, S., Winchell, J.M., Katz, J.M., Erdman, D., Schneider, E., Hicks, L.A., McCullers, J.A., Pavia, A.T., Edwards, K.M., Finelli, L., N. Engl. J. Med., 373, 2015, 415.
7. 7 Musher, D.M., Dowell, M.E., Shortridge, V.D., Flamm, R.K., Jorgensen, J.H., Le Magueres, P., Krause, K.L., N. Engl. J. Med., 346, 2002, 630.
8. 8 Spellberg, B., N. Engl. J. Med., 370, 2014, 1861.
9. 9 Zheng, X., Lee, S., Selvarangan, R., Qin, X., Tang, Y.W., Stiles, J., Hong, T., Todd, K., Ratliff, A.E., Crabb, D.M., Xiao, L., Atkinson, T.P., Waites, K.B., Emerg. Infect. Dis., 21, 2015, 1470.
10. 10 Okada, T., Morozumi, M., Tajima, T., Hasegawa, M., Sakata, H., Ohnari, S., Chiba, N., Iwata, S., Ubukata, K., Clin. Infect. Dis., 55, 2012, 1642.
11. 11 Suzuki, Y., Itagaki, T., Seto, J., Kaneko, A., Abiko, C., Mizuta, K., Matsuzaki, Y., Pediatr. Infect. Dis. J., 32, 2013, 237.
12. 12 Bebear, C., Clin. Infect. Dis., 55, 2012, 1650.
13. 13 Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., Dowell, S.F., File, T.M. Jr., Musher, D.M., Niederman, M.S., Torres, A., Whitney, C.G., Clin. Infect. Dis., 44, 2007, S27.
14. 14 Currie, C.J., Berni, E., Jenkins-Jones, S., Poole, C.D., Ouwens, M., Driessen, S., de Voogd, H., Butler, C.C., Morgan, C.L., Br. Med. J., 349, 2014, g5493.
15. 15 Hess, G., Hill, J.W., Raut, M.K., Fisher, A.C., Mody, S., Schein, J.R., Chen, C.C., Adv. Ther., 27, 2010, 743.
16. 16 FDA Drug Safety Communication. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. May 12, 2016. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm.
17. 17 Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J., Morris, A.J., Luna, C.M., Snydman, D.R., Ko, W.C., Chedid, M.B., Hui, D.S., Andremont, A., Chiou, C.C., Am. J. Respir. Crit. Care Med., 170, 2004, 440.
18. 18 Rodriguez, A., Mendia, A., Sirvent, J.M., Barcenilla, F., de la Torre-Prados, M.V., Sole-Violan, J., Rello, J., Crit. Care Med., 35, 2007, 1493.
19. 19 Wunderink, R.G., Mandell, L., Semin. Resp. Crit. Care Med., 33, 2012, 311.
20. 20 Reynolds, C.A., Finkelstein, J.A., Ray, G.T., Moore, M.R., Huang, S.S., Antimicrob. Resist. Infect. Control., 3, 2014, 16.
21. 21 Shi, J., Montay, G., Bhargava, V.O., Clin. Pharmacokinet., 44, 2005, 915.
22. 22 Shain, C.S., Amsden, G.W., Ann. Pharmacother., 36, 2002, 452.
23. 23 Zeitlinger, M., Wagner, C.C., Heinisch, B., Clin. Pharmacokinet., 48, 2009, 23.
24. 24 FDA Briefing Package for Telithromycin (Ketek), Anti-Infective Drugs Advisory Committee Meeting, 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_A-FDA%20Cover%20Page.pdf.
25. 25 Ross, D.B., N. Engl. J. Med., 356, 2007, 1601.
26. 26 Brinker, A.D., Wassel, R.T., Lyndly, J., Serrano, J., Avigan, M., Lee, W.M., Seeff, L.B., Hepatology, 49, 2009, 250.
27. 27 FDA Briefing Document and Advisory Committee Meeting for Telithromycin (Ketek), 2006. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4266b1-00-index.htm.
28. 28 Leitner, J.M., Graninger, W., Thalhammer, F., Infection, 38, 2010, 3.
29. 29 FDA Guidance for Industry-Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment, 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm123686.pdf.
30. 30 Fernandes, P., Use of Antibiotic Core Structures to Generate New and Useful Macrolide Antibiotics. Demain, A.L., Sanchez, S., (eds.) Antibiotics: Current Innovations and Future Trends, 2015, Caister Academic Press, Norfolk, UK, 375–393 Chapter 20.
31. 31 Hammerschlag, M.R., Expert. Opin. Invest. Drugs, 17, 2008, 387.
32. 32 FDA Briefing Document, Anti-Infective Drugs Advisory Committee Meeting. Cethromycin for the Treatment of Community-Acquired Bacterial Pneumonia, June 2, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM161847.pdf.
33. 33 Rostovtsev, V.V., Green, L.G., Fokin, V.V., Sharpless, K.B., Angew. Chem. Int. Ed., 41, 2002, 2596.
34. 34 Tornoe, C.W., Christensen, C., Meldal, M., J. Org. Chem., 67, 2002, 3057.
35. 35 Llano-Sotelo, B., Dunkle, J., Klepacki, D., Zhang, W., Fernandes, P., Cate, J.H., Mankin, A.S., Antimicrob. Agents Chemother., 54, 2010, 4961.
36. 36 Evrard-Todeschi, N., Gharbi-Benarous, J., Gaillet, C., Verdier, L., Bertho, G., Lang, C., Parent, A., Girault, J.P., Bioorg. Med. Chem., 8, 2000, 1579.
37. 37 Still, J.G., Schranz, J., Degenhardt, T.P., Scott, D., Fernandes, P., Gutierrez, M.J., Clark, K., Antimicrob. Agents Chemother., 55, 2011, 1997.
38. 38 Oldach, D., Clark, K., Schranz, J., Das, A., Craft, J.C., Scott, D., Jamieson, B.D., Fernandes, P., Antimicrob. Agents Chemother., 57, 2013, 2526.
39. 39 Harrison, C., Nat. Rev. Drug Disc., 8, 2009, 690.
40. 40 Taly, A., Corringer, P.J., Guedin, D., Lestage, P., Changeux, J.P., Nat. Rev. Drug Disc., 8, 2009, 733.
41. 41 Bertrand, D., Bertrand, S., Neveu, E., Fernandes, P., Antimicrob. Agents Chemother., 54, 2010, 5399.
42. 42 Valera, S., Ballivet, M., Bertrand, D., Proc. Natl. Acad. Sci. U.S.A., 89, 1992, 9949.
43. 43 Tracey, K.J., Nature, 420, 2002, 853.
44. 44 Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S., Li, J.H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C.J., Tracey, K.J., Nature, 421, 2003, 384.
45. 45 Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., Wang, H., Abumrad, N., Eaton, J.W., Tracey, K.J., Nature, 405, 2000, 458.
46. 46 Hiramoto, T., Chida, Y., Sonoda, J., Yoshihara, K., Sudo, N., Kubo, C., Gastroenterology, 134, 2008, 2122.
47. 47 Darpo, B.; Philip, S.; Zhou, M.; Jamieson, B.; Fernandes, P.; Keedy, K.; Oldach, D. Solithromycin, a 4th Generation Macrolide and the 1st Fluoroketolide, Does Not Prolong the QTc Interval: Results of a Definitive QT Study. In 25th Eur. Congr. Clin. Microb. Infect. Dis. Copenhagen, Denmark, 2015, p LBEV0081a.
48. 48 Perret, C., Lenfant, B., Weinling, E., Wessels, D.H., Scholtz, H.E., Montay, G., Sultan, E., Chemotherapy, 48, 2002, 217.
49. 49 Jamieson B.; Rewerska, B.; Tanaseanu, C.M.; Vucinic-Mihailovic, V.; Taylor, D.; Sheets, A.; Keedy, K.; Oldach, D.; Fernandes, P. SOLITAIRE-IV: A Phase 3 IV to Oral Trial Evaluating Solithromycin in Adults with Community-Acquired Bacterial Pneumonia. In 26th Eur. Cong. Clin. Microbiol. Infect. Dis. Amsterdam, Netherlands, 2016, p P1338.
50. 50 Barrera, C.M., Mykietiuk, A., Metev, H., Nitu, M.F., Karimjee, N., Doreski, P.A., Mitha, I., Tanaseanu, C.M., Molina, J.M., Antonovsky, Y., Van Rensburg, D.J., Rowe, B.H., Flores-Figueroa, J., Rewerska, B., Clark, K., Keedy, K., Sheets, A., Scott, D., Horwith, G., Das, A.F., Jamieson, B., Fernandes, P., Oldach, D., Lancet Infect. Dis., 16, 2016, 421.
51. 51 Li, X., Atkinson, T.P., Hagood, J., Makris, C., Duffy, L.B., Waites, K.B., Pediatr. Infect. Dis. J., 28, 2009, 693.
52. 52 He, X.Y., Wang, X.B., Zhang, R., Yuan, Z.J., Tan, J.J., Peng, B., Huang, Y., Liu, E.M., Fu, Z., Bao, L.M., Zou, L., Diagn. Microbiol. Infect. Dis., 75, 2013, 22.
53. 53 Gonzalez, D.; Al-Uzri, A.; Bradley, J.; James, L.; Adler-Shohet, F.; Mendley, S.; Moffett, K.; Daudjee, M.; Dehority, W.; Bosheva, M.; Tsonkova, E.; Cinoman, M.; Hernandez, R.; Hornik, C.; Fernandes, P.; Cohen-Wolkowiez, M. Pharmacokinetics and Safety of Intravenous Solithromycin in Children ⩾6 Years of Age. In 34th Eur. Soc. Pediatr. Infect. Dis. Brighton, UK, 2016.
54. 54 Gonzalez, D., Palazzi, D.L., Bhattacharya-Mithal, L., Al-Uzri, A., James, L.P., Bradley, J., Neu, N., Jasion, T., Hornik, C.P., Smith, P.B., Benjamin, D.K. Jr., Keedy, K., Fernandes, P., Cohen-Wolkowiez, M., Antimicrob. Agents Chemother., 60, 2016, 2572.
55. 55 Kirkcaldy, R. New Treatment Guidelines for Gonorrhea: Antibiotic Change. August 13, 2012. http://www.medscape.com/viewarticle/768883.
56. 56 Hook, E.W. III, Golden, M., Jamieson, B.D., Dixon, P.B., Harbison, H.S., Lowens, S., Fernandes, P., Clin. Infect. Dis., 61, 2015, 1043.
57. 57 Keelan, J.A., Kemp, M.W., Payne, M.S., Johnson, D., Stock, S.J., Saito, M., Fernandes, P., Newnham, J.P., Antimicrob. Agents Chemother., 58, 2014, 447.
58. 58 Keelan, J.A., Payne, M.S., Kemp, M.W., Ireland, D.J., Newnham, J.P., Front. Immunol., 2016, 7.
59. 59 Keelan, J.A., Pugazhenthi, K., Placenta, 35, 2014, 1043.
60. 60 Piccinelli, G., Fernandes, P., Bonfanti, C., Caccuri, F., Caruso, A., De Francesco, A.M., Antimicrob. Agents Chemother., 58, 2014, 1693.
61. 61 Miura, Y., Payne, M.S., Keelan, J.A., Noe, A., Carter, S., Watts, R., Spiller, O.B., Jobe, A.H., Kallapur, S.G., Saito, M., Stock, S.J., Newnham, J.P., Kemp, M.W., Antimicrob. Agents Chemother., 58, 2014, 5413.
62. 62 Furfaro, L.L., Spiller, O.B., Keelan, J.A., Payne, M.S., Int. J. Antimicrob. Agents, 46, 2015, 319.
63. 63 Waites, K.B., Crabb, D.M., Duffy, L.B., Antimicrob. Agents Chemother., 53, 2009, 2139.
64. 64 Hardy, D.J.; Vicino, D.; Keedy, K.; Fernandes, P. Susceptibility of Gardnerella vaginalis to Solithromycin (CEM-101). In 54th Intersci. Conf. Antimicrob. Agents Chemother. Washington, D.C., 2014, p F-1616.
65. 65 Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Higaki, M., Mikura, S., Goto, H., Barnes, P.J., Ito, K., J. Pharmacol. Exp. Ther., 345, 2013, 76.
66. 66 Clement, A., Tamalet, A., Leroux, E., Ravilly, S., Fauroux, B., Jais, J.P., Thorax, 61, 2006, 895.
67. 67 Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Charron, C., Barnes, P.J., Ito, K., Br. J. Pharmacol., 169, 2013, 1024.
68. 68 Albert, R.K., Connett, J., Bailey, W.C., Casaburi, R., Cooper, J.A. Jr., Criner, G.J., Curtis, J.L., Dransfield, M.T., Han, M.K., Lazarus, S.C., Make, B., Marchetti, N., Martinez, F.J., Madinger, N.E., McEvoy, C., Niewoehner, D.E., Porsasz, J., Price, C.S., Reilly, J., Scanlon, P.D., Sciurba, F.C., Scharf, S.M., Washko, G.R., Woodruff, P.G., Anthonisen, N.R., N. Engl. J. Med., 365, 2011, 689.